Welcome to our dedicated page for Harrow news (Ticker: $HROW), a resource for investors and traders seeking the latest updates and insights on Harrow stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Harrow's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Harrow's position in the market.
Rhea-AI Summary
Harrow (Nasdaq: HROW) will release its first quarter 2024 financial results on May 13, 2024, followed by a conference call on May 14, 2024, to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
-
Rhea-AI Summary
Melt Pharmaceuticals, Inc. completes a Series B Preferred Stock financing of $24 million, increasing pre-money valuation by 150%. The funding will support the development of MELT-300, a non-IV, non-opioid tablet for procedural sedation. The Phase 3 program started in Q1 2024, with topline results expected in Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
-
Rhea-AI Summary
Harrow (HROW) reports a successful year with revenues of $130.2 million, a 47% increase from 2022, but a net loss of $(24.4 million). Adjusted EBITDA rose to $28.1 million. The company emphasizes growth in ophthalmic pharmaceuticals, launching new products and attracting talent for future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
Rhea-AI Summary
Harrow (Nasdaq: HROW) to Release Financial Results for Q4 and Year-End 2023, Host Conference Call on March 20, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
-
Rhea-AI Summary
Harrow, Inc. (HROW) and Apotex Inc. announce an exclusive out-licensing agreement for ophthalmic pharmaceutical products in Canada. Apotex will market and distribute VERKAZIA and Cationorm PLUS while seeking approval for VEVYE, IHEEZO, and ZERVIATE. The partnership aims to expand product offerings, improve patient quality of life, and strengthen therapeutic options in the Canadian market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.87%
Tags
-
Rhea-AI Summary
Harrow (Nasdaq: HROW) has appointed Adrienne Graves, Ph.D., and Lauren Silvernail to its Board of Directors, bringing the total number of members to six. The company aims to leverage their expertise to execute its Strategic Plan and maximize stockholder value by leveraging its dynamic product portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
Rhea-AI Summary
Harrow (Nasdaq: HROW) launches VEVYE® (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine-based product indicated for treating both the signs and symptoms of dry eye disease (DED) in the U.S. VEVYE offers rapid onset with clinically and statistically meaningful improvement beginning as early as 15 days, with sustained improvement over 56 weeks. VEVYE patients have access to a 100% money-back guarantee program. The drug is powered by a unique combination of cyclosporine and a water-free semifluorinated alkane delivery vehicle, solving an unmet need for eyecare professionals treating the tens of millions of American chronic dry eye disease sufferers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
-
Rhea-AI Summary
Melt Pharmaceuticals, Inc. (Melt) provided a corporate update, announcing the success of MELT-300 in its Phase 2 Pivotal Efficacy and Safety Study for procedural sedation in cataract surgery. The non-IV, non-opioid tablet, using Catalent Inc.'s fast-dissolving Zydis® delivery technology, is expected to begin Phase 3 program activities in the first quarter of 2024. Additionally, Melt settled its debt with its largest shareholder, Harrow, Inc. (Nasdaq: HROW), and secured funding for the Phase 3 program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.93%
Tags
-
Rhea-AI Summary
Harrow (Nasdaq: HROW) has partnered with three leading healthcare technology platforms to expand U.S. availability of VEVYE® (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine-based product indicated for treating both signs and symptoms of dry eye disease (DED). The partnerships with PhilRx, Apollo Care, and PARx Solutions aim to simplify the prior authorization process, establish copay program deployment, and help prescribers overcome challenges. Harrow's commitment to patient access and innovative, affordable ophthalmic pharmaceutical products is reflected in its market access program for VEVYE.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.93%
Tags
Rhea-AI Summary
Harrow (Nasdaq: HROW) has completed the transfer of the New Drug Application (NDA) for TRIESENCE, a synthetic corticosteroid used for various eye conditions, ahead of the previously agreed date. The company has also acquired the U.S. commercial rights to TRIESENCE and is making progress in manufacturing commercial batches. Harrow is implementing market access, marketing, inventory management, and brand-leveraging strategies to re-launch TRIESENCE in the U.S., showing a promising outlook for the company's future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
Harrow, Inc.
Nasdaq:HROW
HROW Rankings
HROW Stock Data
376.46M
26.55M
14.59%
66.11%
17.31%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
NASHVILLE
About HROW
harrow health, inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the united states. the company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. it also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. its products portfolio includes topical eye drop drug candidates, including surf-100 and surf-200; surf-300, an oral capsule for treating patients suffering from ocular surface diseases, and ded signs and symptoms; klarity drops to protect and rehabilitate the ocular surface pathology for patients with ded; melt-100, a drug that is administered sublingually for conscious sedation during cataract surgery; may-66 that is used for the treatment of symptoms associated with peyronie's diseas